Ahmad Awada, Martine J. Piccart-Gebhart. (2008) Management of HER-2/neu-positive metastatic breast cancer. European Journal of Cancer Supplements 6 , 2-9 /Winer PE, Piccart-Gebhart MJ, Rugo HS, et al. Management of HER-2 positive breast cancer. In: ASCO Educational Book. Alexandria: ...
To investigate whether the administration of trastuzumab was effective as adjuvant treatment for HER2-positive breast cancer if used after completion of the primary treatment for mortality, recurrence, metastases and second tumor no breast cancer rate. Also, the another objective the current review was ...
HER- 2/neu-positive breast cancer is an aggressive type that has a high rate of recurrence and short disease-free intervals after adjuvant (postoperative) chemotherapy [4]. Trastuzumab (Herceptin®; F. Hoffmann-La Roche Ltd., Basel, Switzerland), a monoclonal antibody directed against HER-2,...
HER-2/neu status is important information that is needed to guide therapy in patients with HER-2/neu positive breast cancer; therefore, accurate determination of HER-2/neu status by IHC or FISH is essential to providing appropriate treatment. Many studies now demonstrate that the HER-2/neu sta...
HER-2又称ERBB2、EGFR2或NEU,属于上皮因子受体家族成员,该上皮因子受体家族成员还包括EGFR(HER1/ERBB1)、HER-2(ERBB2)、HER3(ERBB3)、HER4(ERBB4)[12]。HER-2是由17号染色体上的HER-2基因调控编码的一种酪氨酸激酶I型跨膜受体,与其他上皮因子家族受体一样由细胞外结构域(负责与配体结合和二聚体的形成)...
The purpose of the study was to determine the utility of quantitation of the extracellular domain (ECD) of the HER-2/neu receptor in the serum for predicting response to treatment in patients with primary breast cancer receiving neoadjuvant therapy. HER-2/neu ECD was measured in sera ob...
Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immuno-staining and adjuvant therapy. Cancer 73:2359-2365, 1994 Google Scholar Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY...
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives Article 08 January 2024 Introduction About 20% of breast cancers are driven by amplification of the ERBB2 gene and overexpression of its gene product, the HER2 protein. A large body of...
“HER2 expression identifies dynamic functional states within circulating breast cancer cells.” Nature vol. 537,7618 (2016): 102-106. doi:10.1038/nature19328 Rugo, Hope S et al. “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A ...
In contrast, Her-2/neu negative breast cell lines did not exhibit any enhanced cytotoxicity by the combination. The Ad-mda7/Herceptin combination treatment induced a G2/M cell cycle block and high levels of apoptosis in Her-2/neu positive cells. By western blot analyses, the combination of ...